Open report — full analysis, no account required.
Sign up to generate reports and read filings that aren't on the open list.
Get notified when ACH files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsRed Flags Detected
- Debt Refinancing At Substantially Higher Rates (9.000%-9.750% Vs. 4.500%-6.625%) (new) — The company is refinancing existing debt at roughly double the interest rate, indicating deteriorated creditworthiness and significantly higher future interest expense.
- Exchange Offers Include Consent to Eliminate Substantially All Covenants and Certain Events of Default (new) — The company is seeking to strip creditor protections from existing note indentures, reducing bondholder safeguards against future deterioration.
- Filing Warns Failure to Complete Transactions Could Materially Adversely Affect Financial Condition (new) — The company explicitly states it is in a precarious financial position requiring debt restructuring to avoid distress, indicating execution risk is material.
- Loss of Large Commercial Payor Contract Representing $335-345m Revenue (12-13% of Total) (new) — The company lost a major customer generating material revenue and EBITDA, requiring significant operational restructuring and contributing to near-term revenue decline.
Accendra Health secures $326M debt refinancing to extend maturities amid contract loss
Filed May 11, 2026 · Period ending May 11, 2026 · ~2 min read
Key Changes
-
high
Company entered commitment letter for $326.25M new 9.000% first-lien notes due 2032 and exchange of existing 4.500%/6.625% notes into 9.000%/9.750% secured notes, with creditor support from 100% of 2029 noteholders and 83% of 2030 noteholders.
Item 1.01 — Entry into a Material Definitive Agreement verify on EDGAR → -
high
Refinancing extends weighted average debt maturity from 2.7 years to 5.5 years and reduces funded debt by $116M through exchange, addressing near-term maturities but at substantially higher interest rates (9.000%-9.750% vs. 4.500%-6.625%).
Exhibit 99.1 view on EDGAR → -
high
Company lost large commercial payor contract generating $335-345M annual revenue and $35-45M EBITDA; implementing capacity adjustment and cost realignment plan including footprint reduction and organizational redesign.
Exhibit 99.1 view on EDGAR → -
high
Term loan lenders agreed to waive mandatory prepayment requirements for up to $400M of asset sale proceeds, suggesting significant asset dispositions are contemplated and giving company flexibility to retain sale proceeds.
Item 1.01 — Entry into a Material Definitive Agreement verify on EDGAR → -
high
Company projects FY26 revenue of $2,610M (down 5.5% YoY) and FY27 revenue of $2,724M (up 4.3%), with adjusted EBITDA of $345M and $363M respectively; near-term decline reflects payor contract loss with recovery expected in FY27.
Exhibit 99.1 view on EDGAR →
Summary
Accendra Health disclosed a comprehensive debt refinancing driven by financial distress following the loss of a major commercial payor contract and the December 2025 divestiture of its Products & Healthcare Services segment.
The company secured commitments from creditors holding substantially all its 2029 notes and 83% of its 2030 notes to exchange existing 4.500%-6.625% unsecured debt into new 9.000%-9.750% secured notes due 2032-2033, alongside $326.25 million of new first-lien financing.
While the transaction extends the weighted average debt maturity from 2.7 to 5.5 years and reduces funded debt by $116 million, it comes at a steep cost: interest rates roughly double, and the company is seeking to eliminate substantially all covenants and certain default provisions from existing indentures, stripping creditor protections. The refinancing addresses immediate liquidity concerns but reflects underlying operational challenges. The company lost a payor contract generating $335-345 million in annual revenue (12-13% of total) and $35-45 million in EBITDA, forcing capacity adjustments and cost realignment including footprint reduction and organizational redesign. Management projects FY26 revenue will decline 5.5% year-over-year to $2,610 million before recovering to $2,724 million in FY27. The filing explicitly warns that failure to complete the debt transactions could materially adversely affect the company's financial condition, underscoring execution risk. Term loan lenders also agreed to waive mandatory prepayment requirements for up to $400 million of asset sale proceeds, suggesting further divestitures may be necessary to stabilize the balance sheet.
Section-by-Section Diff
Event · Item 1.01 — Entry into a Material Definitive Agreement
Accendra Health entered into a commitment letter for a $326.25M debt refinancing involving new secured notes and credit facility amendments.
Added in current filing · verify on EDGAR →
On May 11, 2026, Accendra Health, Inc. (the “Company”) entered into a Commitment and Consent Letter (the “Commitment Letter”) with certain institutions that are (a) (i) holders of the Company’s 4.500% Senior Notes due 2029 (the “2029 Notes”) and 6.625% Senior Notes due 2030 (the “2030 Notes” and, together with the 2029 Notes, the “Existing Notes”), collectively holding approximately all of the outstanding principal amount of the 2029 Notes and approximately 83% of the outstanding principal amount of the 2030 Notes as of May 11, 2026
The company secured commitments from holders of substantially all its 2029 Notes and 83% of its 2030 Notes to participate in a comprehensive debt restructuring. This broad creditor support significantly increases the likelihood of successful execution of the refinancing transactions.
Added in current filing · verify on EDGAR →
the Company’s agreement (a) to offer $326.25 million in aggregate principal amount of newly issued 9.000% Senior Secured First Lien Notes due 2032 (the “First Lien Notes,” such notes issued for cash the “New Money First Lien Notes” and such offer, the “New Money Notes Issuance”) and (b) conduct the Exchange Offers and the Consent Solicitations
The company will issue $326.25 million of new 9.000% Senior Secured First Lien Notes due 2032, representing new money financing. The 9.000% rate is substantially higher than the existing 4.500% and 6.625% notes being refinanced, reflecting increased borrowing costs. Backstop parties committed to purchase $261.0 million at par plus up to $65.25 million more if needed, in exchange for a 3.50% cash fee.
Added in current filing · verify on EDGAR →
each Revolving Lender Commitment Party has committed to provide on the early settlement date of the Offers, subject to certain customary conditions, its applicable portion of a $300.0 million new revolving credit facility (the “New Revolving Credit Facility”) due in 2030, subject to a springing maturity of 91 days inside intervening maturities of certain indebtedness in excess of $25.0 million in aggregate principal amount
The company secured commitments for a new $300.0 million revolving credit facility due 2030, which will replace the existing revolving facility. The facility includes a springing maturity provision that accelerates repayment to 91 days before other debt maturities exceeding $25.0 million.
Event · Item 7.01 — Regulation FD Disclosure
Accendra Health furnished an investor presentation related to debt restructuring discussions and pending offers/consent solicitations.
Added in current filing · verify on EDGAR →
The Company is furnishing an investor presentation attached hereto as Exhibit 99.1 pursuant to Item 7.01 of Form 8-K. The investor presentation includes certain information previously shared with the Commitment Parties during the course of the discussions preceding the execution of the Commitment Letter.
Accendra Health disclosed an investor presentation that was previously shared with Commitment Parties during discussions leading to a Commitment Letter. The presentation is furnished under Regulation FD, meaning it is not formally filed and provides transparency about information shared with potential financing parties.
Added in current filing · verify on EDGAR →
The Offers and Consent Solicitations are subject to the satisfaction or waiver of a number of conditions. The Company reserves the right, in its sole discretion, to amend the terms of the Offers and Consent Solicitations. The Offers and Consent Solicitations may not be completed as contemplated or at all. If the Company is unable to complete the Offers and Consent Solicitations or any other alternative transactions, on favorable terms or at all, due to market conditions or otherwise, its financial condition could be materially adversely affected.
The company is conducting offers and consent solicitations related to debt restructuring, subject to multiple conditions and potential amendments. The filing explicitly warns that failure to complete these transactions could materially adversely affect the company's financial condition, indicating the company is in a precarious financial position requiring debt restructuring to avoid distress.
Added in current filing · verify on EDGAR →
The New Notes to be offered in the Offers have not been registered under the Securities Act or any state securities laws, and unless so registered, the New Notes may not be offered or sold in the United States or to any U.S. persons except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and applicable state securities laws.
The company plans to issue New Notes as part of the debt restructuring offers. These notes are being offered through a private placement exempt from Securities Act registration, limiting their availability to qualified institutional buyers or accredited investors.
Event · Exhibit 99.1
Accendra Health disclosed a comprehensive debt refinancing and exchange transaction to extend maturities and reduce funded debt.
Added in current filing · view on EDGAR →
The Comprehensive Transaction contemplates (i) replacing the existing RCF with a new longer-dated RCF of up to $300mm, (ii) refinancing the TLA through a long-dated new money 1L issuance, and (iii) exchanging the Unsecured Notes into new long-dated secured bonds
Accendra Health is proposing a multi-part transaction to refinance its capital structure. The company will replace its existing revolving credit facility with a new $300 million facility, refinance its Term Loan A with new first-lien notes, and exchange existing unsecured notes into new secured second-lien bonds. An ad hoc group representing over 90% of the unsecured notes has committed to the transaction.
Added in current filing · view on EDGAR → · paraphrased
Dec 2025: Products & Healthcare Services (P&HS) segment acquired by Platinum Equity
Accendra Health completed the sale of its Products & Healthcare Services business segment to Platinum Equity in December 2025. This divestiture transforms the company into a pure-play home-based care platform focused on durable medical equipment and chronic disease management. The P&HS business had been a material source of cash consumption, with net operating and investing cash outflows totaling $311 million in FY25.
Added in current filing · view on EDGAR →
Total Revenue $2,610 $2,724 ... Adjusted EBITDA $345 $363 ... Unlevered Free Cash Flow $222 $206
Accendra Health projects FY26 revenue of $2,610 million (down 5.5% year-over-year) and FY27 revenue of $2,724 million (up 4.3%). Adjusted EBITDA is projected at $345 million and $363 million for FY26 and FY27, respectively, with unlevered free cash flow of $222 million and $206 million. The near-term revenue decline reflects the impact of the large payor contract loss, with recovery expected in FY27.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Jun 21, 2026 · How we verify